Cardiac Hypertrophy Cell Models for Research

Cardiac hypertrophy is a major public health concern worldwide, affecting approximately 2-3% of the global population. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, with heart failure—often a consequence of pathological hypertrophy—contributing to over 17 million deaths annually. The prevalence of hypertension, a primary driver of cardiac hypertrophy, is estimated at 1.28 billion adults aged 30-79 years. The clinical impact is substantial: patients with pathological hypertrophy have a 5-year survival rate of approximately 50% once heart failure develops, as reported by the National Cancer Institute (NCI) and other cardiovascular registries. Key risk factors include hypertension, valvular disease, and genetic mutations in sarcomeric genes. The economic burden is immense, with heart failure costing the US healthcare system over $30 billion annually.

Cardiac hypertrophy is an ideal model for mechanistic studies due to its well-characterized pathophysiology and the availability of numerous in vitro and in vivo models. The disease encompasses both physiological (adaptive) and pathological (maladaptive) forms, allowing researchers to dissect signaling pathways that distinguish beneficial from detrimental growth. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Gene Expression Omnibus (GEO), provide extensive transcriptomic and proteomic data. Open questions include the molecular switch between compensated and decompensated hypertrophy, the role of non-coding RNAs, and the identification of novel therapeutic targets. Gene-edited cell models enable precise manipulation of specific genes to study their causal roles in hypertrophy progression.

While cardiac hypertrophy is not a cancer, it shares common signaling pathways with oncogenesis, such as the PI3K/AKT and MAPK pathways. The major pathways involved in pathological hypertrophy include:

1. Gq-coupled receptor signaling: Activation of Gq-coupled receptors (e.g., angiotensin II type 1 receptor) leads to phospholipase C activation, increasing intracellular calcium and activating protein kinase C (PKC).

2. MAPK/ERK pathway: Growth factors and mechanical stress activate Ras, leading to sequential phosphorylation of Raf, MEK, and ERK, which translocate to the nucleus to activate transcription factors.

3. PI3K/AKT pathway: Insulin and growth factors activate PI3K, generating PIP3, which recruits AKT to the membrane. AKT phosphorylates downstream targets like mTOR, promoting protein synthesis and cell growth.

4. Calcineurin/NFAT pathway: Sustained elevation of intracellular calcium activates calcineurin, which dephosphorylates NFAT, allowing its nuclear translocation and activation of hypertrophic genes.

Data from ClinVar and COSMIC databases.

Key signaling networks in cardiac hypertrophy include:

• • MAPK cascade: Key nodes include Ras, Raf, MEK1/2, ERK1/2, and downstream transcription factors like Elk-1 and c-Myc.
• • PI3K/AKT/mTOR pathway: Nodes include PI3K, PIP3, AKT, TSC1/2, mTORC1, and S6K1.
• • Calcineurin/NFAT signaling: Nodes include calcineurin (PPP3CA), NFATc4, and GATA4.
• • JAK/STAT pathway: Nodes include JAK1/2, STAT3, and SOCS3.
• • Wnt/β-catenin pathway: Nodes include Wnt ligands, Frizzled receptors, GSK3β, and β-catenin.

These pathways are interconnected and often converge on transcription factors that regulate fetal gene expression, such as NPPA (ANP), NPPB (BNP), and MYH7.

Organoids derived from iPSC-CMs offer a 3D environment that better recapitulates cardiac tissue architecture and cell-cell interactions. They are useful for studying hypertrophy in a more physiologically relevant context.

• • Transverse aortic constriction (TAC): Surgical model that induces pressure overload, leading to concentric hypertrophy.
• • Angiotensin II infusion: Chronic infusion via osmotic pumps induces hypertension and hypertrophy.
• • Isoproterenol administration: β-adrenergic agonist that causes hypertrophy.
• • Genetic models: Knockout or transgenic mice with mutations in sarcomeric genes (e.g., MYH7 R403Q) or signaling molecules (e.g., calcineurin overexpression).
• • Patient-derived xenografts (PDX): Not applicable for cardiac hypertrophy, but relevant for cancer research.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models for cardiac hypertrophy. These models are generated by introducing precise mutations or knockouts into human induced pluripotent stem cells (iPSCs) or immortalized cardiomyocyte cell lines like AC16. Examples include:

• • MYH7 knockout cell line: Ablation of MYH7 to study its role in sarcomere function and hypertrophy.
• • TNNT2 R92Q knock-in cell line: Introduction of a hypertrophic cardiomyopathy-associated mutation to model the disease.
• • ACTC1 E101K knock-in cell line: A point mutation in actin that disrupts sarcomere integrity.

These isogenic lines are sequence-verified and commercially available, providing a reliable and reproducible platform for drug discovery and functional genomics. They allow researchers to study the impact of specific genetic alterations in a controlled background, accelerating the development of targeted therapies.

Gene-edited cell lines are essential for functional genomics studies to validate the role of genes in cardiac hypertrophy. For example, knocking out a gene of interest and observing the effect on hypertrophy markers (e.g., ANP, BNP) can confirm its involvement. Conversely, introducing a disease-associated mutation can establish causality. CRISPR screens using pooled libraries can identify novel genes that modulate hypertrophy, providing a comprehensive view of the genetic landscape.

Isogenic pairs—where one cell line carries a specific mutation and the other is wild-type—are ideal for drug screening. They allow researchers to identify compounds that selectively inhibit the mutant phenotype while sparing the normal cells. This approach is particularly useful for developing precision therapies for genetic forms of hypertrophy. Additionally, gene-edited cells can be used to model drug resistance by introducing mutations that confer resistance to existing therapies, enabling the development of next-generation drugs.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of a specific mutation. For example, in cells carrying a MYH7 mutation, knocking out a gene that is synthetically lethal can lead to cell death, revealing potential therapeutic targets. Such screens can also uncover biomarkers for early detection of hypertrophy or for monitoring treatment response.